Breaking AI & Tech News Analyzed

Acclaimed director Ken Loach revisits his 2016 film I, Daniel Blake, a poignant portrayal of poverty and the struggles faced by those in need. The film, which sparked controversy upon its release, shed light on the cruel realities of a system that vilifies the vulnerable.Loach reveals that the film was born out of a time of 'mean-spiritedness,' where those who needed support were met with punishment. The story follows Daniel Blake, a character who desperately wants to work but is thwarted by a system designed to fail him.The film's screenwriter, Paul Laverty, conducted extensive research, including a visit to a Glasgow food bank, where he encountered a young man who had not eaten in two to three days. This harrowing experience inspired a pivotal scene in the film, where Katie, played by Hayley Squires, is forced to eat cold baked beans from a tin.Loach notes that at the time of the film's release, the notion of food banks as an institution was unimaginable. However, food banks are now a normalized part of society, with many people relying on them to survive. The film's portrayal of poverty and hunger was met with resistance from some, including Damian Green, who claimed it was a work of fiction. Loach counters that while the characters are fictional, the stories are rooted in truth.Hayley Squires, who played Katie, shares her experience working on the film. She was drawn to the project after meeting Loach and was impressed by his authenticity and warmth. The film's shooting process was unique, with Squires and her co-star Dave Johns working chronologically and improvising scenes.Squires also recounts her preparation for the food bank scene, which included visiting a real food bank and cutting back on food to better understand the experience of hunger. The scene was shot only once, with Loach and the cinematographer Robbie Ryan working to create a sense of empathy and realism.

The Department for Culture, Media and Sport, acting on Historic England’s advice, has awarded Grade II* listed status to a limestone rubble barn on a grassy knoll in the Lake District, joining an elite roster that includes Battersea Power Station and the London Coliseum.Dubbed “Henry’s Castle,” the structure was most recently used as a shelter for livestock, but research suggests it may date back to the 14th century and originally served a high‑status function that remains unknown.Only 5.8% of England’s listed buildings achieve the Grade II* level, indicating they possess “more than special interest.” The barn’s unusual features – a corbelled chimney stack, a stepped garderobe, and a plastered interior showing signs of fire – set it apart from ordinary field barns.Historic England’s listing team leader, Sarah Charlesworth, described the building as “one of those rare structures that raises more questions than it answers,” underscoring its intrigue for scholars and visitors alike.Lake District National Park’s built‑environment adviser, Rose Lord, recalled her 2022 visit, noting that despite layers of animal manure the barn’s architecture hinted at something “very special” – a construction far beyond typical agricultural outbuildings.Four years of meticulous work by archaeologists, architects, and conservation engineers have restored the barn’s most striking element: an oak roof featuring a hand‑finished, chamfered and pegged central truss, a technique associated with high‑quality carpentry of the 14th or 15th centuries.Experts speculate on the barn’s original purpose, ranging from a defensive lookout or hunting lodge to a luxurious summer house. Historic England notes similarities to bastles – fortified farmhouses common along the Anglo‑Scottish border – though the building’s location south of the border makes a strict classification unlikely.Originally converted to domestic use in the 16th or 17th century and later repurposed as a field barn by the 19th century, the structure takes its name from former owner farmer Henry Willison.Lord called the new listing the “cherry on the cake” for the restoration project, highlighting that most buildings of comparable significance have already been recorded in earlier surveys. Interpretation panels and an owl‑nesting box are slated for installation in the coming weeks, adding educational and ecological value to the site.

Conversations about mundane topics are often dreaded, but research suggests that people enjoy them more than they anticipate. A study involving 1,800 volunteers found that participants enjoyed chatting about dull subjects, such as the stock market or vegan diets, more than they expected. The findings indicate that by avoiding potentially dull exchanges, individuals may miss out on the mood boost and health benefits that come with connecting with others. Elizabeth Trinh, a PhD candidate in management and organisations at the University of Michigan, noted that people tend to underestimate how interesting and enjoyable conversations about boring topics can be. Trinh and her colleagues conducted a series of experiments to gauge how people responded to conversations on dull topics. Participants were asked to predict how much they would enjoy discussing topics they considered boring, and then engage in brief conversations about those topics. The results, published in the Journal of Personality and Social Psychology, showed that people consistently found the conversations more enjoyable than they expected. The surprise enjoyment arises because individuals base their expectations on static components, such as the topic and the other person, rather than dynamic components, like the conversation itself. Trinh suggests that people may benefit from lowering the bar for what makes a conversation worth having and reframing conversational goals. Instead of focusing on enjoyment, individuals could think about what they might learn from the conversation. Nicholas Epley, a professor of behavioural science at the University of Chicago, added that the fear of a boring conversation shouldn’t prevent people from starting one. “If a conversation is boring once you’re in it, you also have a surprising amount of power to make it better!”

Meta, the company behind Facebook and Instagram, is reportedly working on an AI version of its CEO, Mark Zuckerberg. This AI clone is being trained on Zuckerberg's mannerisms, tone, and public statements to allow employees to interact with a digital version of their boss.The rationale behind this project is to make Meta's 79,000 employees feel more connected to one of the most influential figures in Silicon Valley. The AI character will be developed using images and the voice of Zuckerberg, with the CEO reportedly taking part in the training process.This move is part of Meta's broader effort to integrate AI into its business operations. The company aims to use AI to lower costs and accelerate work pace. Zuckerberg has emphasized the importance of efficiency, stating that the goal is to 'get more done' by elevating individual contributors and flattening teams.The development of this AI character follows Meta's previous experiments with digital avatars. In 2022, Zuckerberg shared his own avatar in the metaverse, which received public criticism for its graphic quality. The company has since scaled back its metaverse vision, focusing on AI-generated 3D characters for everyday conversations.Meta's investment in AI is part of a larger strategy to remain competitive with tech rivals. The company is pouring billions of dollars into AI research to create 'superintelligence,' a system capable of performing any cognitive task far better than a human.

Recent CDC data reveal a dramatic 1,200% increase in kratom‑related poisonings across the United States over the last ten years, with the most pronounced surge recorded in 2025. Researchers link this rise to the growing presence of 7‑hydroxymitragynine (7‑OH), a synthetically produced compound that mimics kratom’s effects but carries opioid‑like risks. Walter Prozialeck, pharmacology professor at Midwestern University, said the trend was expected, noting that the synthetic alkaloid has entered the market through energy drinks and other products since 2024. Christopher McCurdy of the University of Florida warned that marketing 7‑OH as “enhanced kratom” blurs the line for consumers, turning poison‑control calls into a conflated metric for both natural and synthetic products. By contrast, natural kratom (Mitragyna speciosa)—a Southeast Asian plant used for centuries as a pain reliever—has demonstrated a relatively favorable safety profile in animal and human studies. A 2018 statement from then‑HHS Secretary Brett Giroir rejected the DEA’s push to schedule kratom as a Schedule I substance, citing insufficient evidence of harm. Despite the scientific distinction, several states have moved to implement or propose blanket bans on all kratom products, prompting concern from clinicians and patient advocates. A recent user survey indicated that about 50% of respondents rely on kratom for chronic pain, while roughly 40% use it during addiction recovery. Personal testimonies underscore the plant’s therapeutic role. Jeff Maslan, a 68‑year‑old Californian with severe osteoarthritis, credits kratom with easing opioid withdrawal after multiple surgeries. Similarly, “Steven,” a disabled California resident, describes how kratom eliminated unbearable oxycodone withdrawal symptoms without producing the euphoric “warm fuzzy” feeling typical of opioids. Researchers emphasize that 7‑OH carries genuine opioid hazards, including addiction, severe withdrawal, and respiratory depression that can lead to fatal overdose. In animal models, 7‑OH demonstrated the same respiratory‑depression risk as classic opioids, whereas kratom’s primary alkaloid did not. Prozialeck and colleagues explain that kratom’s pharmacology is more nuanced: it partially activates opioid receptors while also engaging adrenergic and serotonin pathways, resembling a hybrid of a weak opioid and an SNRI‑type antidepressant. This multimodal action likely accounts for its lower euphoric potential and the reported boost in energy among users. Nevertheless, experts caution that kratom is not without risk. Fatal poisonings often involve co‑ingestion of potent opioids such as fentanyl, suggesting that some users may cycle between kratom and stronger substances, raising overdose danger due to reduced opioid tolerance. Additionally, heavy‑metal contamination has been detected in certain kratom batches, though the source—soil, processing, or storage—remains unclear. Given these complexities, the consensus among scholars like Austin Zamarripa (Johns Hopkins) is that natural kratom should remain accessible, while concentrated 7‑OH products merit stricter regulation. “These products may offer meaningful benefits to some individuals, and those benefits could be lost if access is restricted too broadly,” Zamarripa said, urging a differentiated policy approach. As the debate unfolds, patients like Steven worry that a sweeping ban would ignore the nuanced safety profile of the plant. “There’s corn on the cob, there’s high‑fructose corn syrup, there’s whiskey— all derived from corn but fundamentally different,” he remarked, highlighting the need for targeted, evidence‑based regulation rather than a one‑size‑fits‑all prohibition.

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

The US has announced plans to blockade the Strait of Hormuz, a vital waterway through which about 20% of global oil passes. This move comes after ceasefire talks with Iran ended without an agreement over the weekend. The blockade, threatened by President Donald Trump, aims to pressure Iran into reopening the strait, which has been effectively closed since February 28. Trump's announcement on social media stated that the US Navy will begin the process of blockading any and all ships trying to enter or leave the Strait of Hormuz. He accused Iran of 'WORLD EXTORTION' and threatened that any person who attacked US vessels would be 'BLOWN TO HELL!' However, the blockade's scope appears to have been scaled down, with US Central Command (Centcom) stating it would be confined to vessels transiting through Iranian ports, permitting passage of ships headed to ports belonging to America's Gulf allies. The blockade is set to come into effect at 10am ET (2pm GMT). The UK will not be involved in any blockade of the strait, and Australian Prime Minister Anthony Albanese has stated that his country was not asked to participate. Oil prices have surged following Trump's announcement, with US crude increasing 8% to $104.24 a barrel and Brent crude oil rising 7% to $102.29. Experts warn that the blockade could lead to higher oil prices, but much depends on its 'scope and implementation.' The managing director of research at ClearView Energy Partners, Kevin Book, noted that leaner volumes generally mean tighter markets and higher prices. Iranian and/or Houthi reprisals against Gulf producers' alternative routes could drive prices still higher. The blockade could cut off one of the Iranian regime's major sources of funding but might also have a short-term negative effect on global prices. About 100 tankers have transited the strait since the US and Israel started bombing Iran, most carrying Iranian oil products bound for China and India. Iran's Revolutionary Guards have stated that any warships approaching the strait to enforce a blockade would be considered in breach of the current ceasefire and would be dealt with strongly. Trump floated the possibility of a resumption of US strikes inside Iran, citing missile factories as one possible target.

The Israeli military's invasion of southern Lebanon has resulted in the demolition of entire villages, with homes rigged with explosives and razed to the ground in massive remote detonations.Videos posted by the Israeli military and on social media show Israel carrying out mass detonations in the villages of Taybeh, Naqoura, and Deir Seryan along the Israel-Lebanon border. Lebanese media has reported more mass detonations in other border villages.The demolitions came after Israel's minister of defence, Israel Katz, called for the destruction of 'all houses' in border villages 'in accordance with the model used in Rafah and Beit Hanoun in Gaza' to stop threats to communities in northern Israel. The Israeli military destroyed 90% of homes in Rafah, in south Gaza.The tactic of mass destruction of homes in Gaza, where Israel has been accused of committing genocide, was described as domicide by academics, a strategy that is used to systematically destroy and damage civilian housing to render entire areas uninhabitable.The Israeli military has said they are targeting Hezbollah infrastructure such as tunnels and military facilities, which it claims the armed group has embedded in civilian homes, through these demolitions.Israel has said that it will occupy vast swathes of south Lebanon, establishing a 'security zone' in the entire area up to the Litani River, and that displaced people would not be allowed to return to their homes until the safety of Israel's northern cities is guaranteed, prompting concern there will be long-term displacement.Rights groups, however, have said these mass remote detonations could amount to wanton destruction: a war crime. The laws of war prohibit the deliberate destruction of civilian homes, except when necessary for lawful military reasons.'The possibility that Hezbollah may use some civilian structures in Lebanon's border villages for military purposes does not justify the wide-scale destruction of entire villages along the border,' said Ramzi Kaiss, the Lebanon researcher for Human Rights Watch.

GSK has revealed promising early results for its treatment for gynaecological cancers, Mocertatug Rezetecan (Mo-Rez), as its chief executive, Luke Miels, seeks to speed up drug development at the group.The company reported that in an early-stage trial, Mo-Rez shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.GSK acquired the Mo-Rez cancer treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharma in late 2023, and has trialled it in 224 patients around the world, including the UK, over the past year. Few patients needed to stop treatment because of side-effects, the most common being nausea. It is administered every three weeks via intravenous infusion.Combined with data from a separate, intermediate trial in China, these results give GSK the confidence to go straight to late-stage trials, with five clinical studies planned globally in the next few months, including on patients in the UK.Presenting the results at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Puerto Rico, Hesham Abdullah, GSK’s global head of cancer research and development, said: “Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez we now have compelling evidence of a promising clinical profile.”Endometrial cancer affects 1.6 million women globally, with 417,000 new cases each year. Ovarian cancer affects 843,000 people, with 240,000 new cases annually.Abdullah described Mo-Rez as a “key asset” in the company’s growing cancer portfolio, expected to be a blockbuster drug with peak annual sales of more than £2bn, which GSK hopes will help it achieve its 2031 sales target of £40bn.